Evidence map›Paper›PMID 33863377›Full record

ArticleAlzheimer's research & therapy2021

Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods.

James D Doecke, Cindy Francois, Christopher J Fowler, Erik Stoops, Pierrick Bourgeat, Stephanie R Rainey-Smith, Qiao-Xin Li, Colin L Masters, Ralph N Martins, Victor L Villemagne and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

James D DoeckeThe Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia.
Cindy FrancoisADx NeuroSciences, Ghent, Belgium.
Christopher J FowlerUniversity of Melbourne, Melbourne, VIC, Australia.
Erik StoopsADx NeuroSciences, Ghent, Belgium.
Pierrick BourgeatThe Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia.
Stephanie R Rainey-SmithAustralian Alzheimer's Research Foundation, Perth, WA, Australia.
Qiao-Xin LiUniversity of Melbourne, Melbourne, VIC, Australia.
Colin L MastersUniversity of Melbourne, Melbourne, VIC, Australia.
Ralph N MartinsEdith Cowan University, Perth, WA, Australia.
Victor L VillemagneDepartment of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia.
Steven J CollinsUniversity of Melbourne, Melbourne, VIC, Australia.
Hugo Marcel VandersticheleBiomarkable, Ghent, Belgium. hugo.vanderstichele@biomarkable.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration.

methodsBiomarkers for β-amyloidopathy (Aβ1-42, Aβ1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6).

resultsHigh biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability.

conclusionsLevels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesAustraliaBiomarkersHumansPeptide Fragmentstau ProteinsAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseaseAmyloid betaBiomarkersCerebrospinal fluidCollectionConcordance

Identifiers

PMID33863377
PMCPMC8052760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.